224 related articles for article (PubMed ID: 37116111)
1. Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.
Hieken TJ; Kreidieh F; Aedo-Lopez V; Block MS; McArthur GA; Amaria RN
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390614. PubMed ID: 37116111
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.
Ferraresi V; Vari S
Hum Vaccin Immunother; 2022 May; 18(3):1971015. PubMed ID: 34882516
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
Davar D; Tarhini AA; Kirkwood JM
Clin Dermatol; 2013; 31(3):237-50. PubMed ID: 23608443
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
Long GV; Menzies AM; Scolyer RA
J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.
Versluis JM; Reijers ILM; Rozeman EA; Menzies AM; van Akkooi ACJ; Wouters MW; Ch'ng S; Saw RPM; Scolyer RA; van de Wiel BA; Schilling B; Long GV; Blank CU
Eur J Cancer; 2021 May; 148():51-57. PubMed ID: 33735809
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.
Spagnolo F; Croce E; Boutros A; Tanda E; Cecchi F; Mascherini M; Solari N; Cafiero F; Queirolo P
Expert Rev Anticancer Ther; 2020 May; 20(5):403-413. PubMed ID: 32326767
[No Abstract] [Full Text] [Related]
8. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy.
McKean MA; Amaria RN
Cancer Treat Rev; 2018 Nov; 70():144-153. PubMed ID: 30195813
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
10. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
11. Educational Review: Neoadjuvant Approaches to Melanoma.
Sharon CE; Karakousis GC
Ann Surg Oncol; 2022 Dec; 29(13):8492-8500. PubMed ID: 35849287
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma.
Bruce WJ; Koljonen JL; Romanelli MR; Khan AU; Neumeister MW
Clin Plast Surg; 2021 Oct; 48(4):651-658. PubMed ID: 34503725
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Treatments for Advanced Resectable Melanoma.
Liu JY; Lowe M
J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.
Weber J; Glutsch V; Geissinger E; Haug L; Lock JF; Schneider F; Kneitz H; Goebeler M; Schilling B; Gesierich A
Br J Dermatol; 2020 Sep; 183(3):559-563. PubMed ID: 31773720
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Nodal Radiation Therapy for Melanoma in the Era of Immunotherapy.
Mitra D; Bishop A; Guadagnolo BA
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):164-169. PubMed ID: 32544573
[TBL] [Abstract][Full Text] [Related]
18. The Role of Neoadjuvant Therapy in Melanoma.
Kelly ZR; Gorantla VC; Davar D
Curr Oncol Rep; 2020 Jun; 22(8):80. PubMed ID: 32601947
[TBL] [Abstract][Full Text] [Related]
19. Current management of melanoma patients with nodal metastases.
Han D; van Akkooi ACJ; Straker RJ; Shannon AB; Karakousis GC; Wang L; Kim KB; Reintgen D
Clin Exp Metastasis; 2022 Feb; 39(1):181-199. PubMed ID: 33961168
[TBL] [Abstract][Full Text] [Related]
20. Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials.
Patel A; Skitzki J
J Surg Oncol; 2022 Jan; 125(1):38-45. PubMed ID: 34897704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
